Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Motor Activity × Dermatologic × Clear all

Phase

Phase NA 8 Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7 Genitourinary 6 Gastrointestinal 3 Other hematologic neoplasm 2 Lymphoid 2 Head & Neck 1 Dermatologic 1 CNS 1

Conditions

Melanoma 732 Lymphoma, T-Cell, Cutaneous 119 Uveal Melanoma 83 Skin Neoplasms 83 Mycosis Fungoides 78 Sezary Syndrome 65 Neoplasm Metastasis 57 Lymphoma 56 Keratosis, Actinic 56 Carcinoma, Basal Cell 54 Lymphoma, Non-Hodgkin 53 Neoplasms 51 Leukemia, Lymphocytic, Chronic, B-Cell 47 Carcinoma, Renal Cell 47 Carcinoma, Non-Small-Cell Lung 45 Lymphoma, B-Cell, Marginal Zone 44 Precursor Cell Lymphoblastic Leukemia-Lymphoma 43 Lymphoma, Mantle-Cell 43 Lymphoma, Large B-Cell, Diffuse 43 Lymphoma, Follicular 43 Hodgkin Disease 42 Carcinoma, Merkel Cell 42 Lymphoma, Large-Cell, Immunoblastic 41 Burkitt Lymphoma 41 Brain Neoplasms 37 Multiple Myeloma 36 Breast Neoplasms 34 Leukemia, Myeloid, Acute 33 Recurrence 32 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03171064 2023-05-11

Sportivumab

University Hospital Heidelberg

Phase 2 Completed

Melanoma, Motor Activity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡